- Co. received final approval from the U.S. FDA to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne, 4 mg, 8 mg and 12 mg tablets.
- Barr intends to launch its generic Razadyne tablets product immediately.
- Earlier today, Barr announced that the U.S. District Court for the District of Delaware has ruled in favor of its subsidiary in the challenge of U.S. Patent No. 4,663,318 listed by Ortho McNeil Janssen in connection with Razadyne, 4mg, 8mg and 12mg tablets.
- The Court's decision effectively ended the 30-month stay with respect to Barr's generic Razadyne tablets and Barr's generic Razadyne ER, 8 mg, 16 mg and 24 mg extended release capsules.

Other headlines for [BRL]

• BRL Today 05:19am
  Barr Pharmaceuticals Inc EU Commision continues review of Teva aquisition plan
  
• BRL Yesterday 09:07am
  Barr Pharmaceuticals Inc FDA approves NDA for synthetic conjugated Estrogens-A vaginal cream- The FDA has approved the New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream. SCE-A more...
  
• ALKS Yesterday 08:01am
  Alkermes Inc Guides FY09 EPS $1.41-1.53 v $0.25e ($0.20-0.25 prior), Rev $320-346M v $217.1Me ($200-225M prior), Regains full commercialization rights from Cephalon for $16M for VIVITROL- The collaboration more...
  
• BRL 11/26/2008 12:21pm
  Barr Pharmaceuticals Inc Confirms facing a patent challenge for Amrix extended-release capsules 15mg & 30mg- ealier today, Eurand, Cephalon and Anesta AG filed suit in the U.S. District Court for the District of Delaware to more...
  
• MYL 11/26/2008 08:30am
  Mylan Laboratories Inc CEPH and EURX File Patent Infringement Lawsuit Against MYL and BRL- The lawsuit is based upon Abbreviated New Drug Applications filed by Mylan and Barr, each seeking U.S. FDA approval for a generic more...
  

Healthcare sector headlines

• MAKO Today 07:46am
  MAKO Surgical Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System and Its Bicompartmental Knee Resurfacing Implant System- Announced it received two 510(k) clearances from the US FDA to more...
  
• UNH Today 07:40am
  UnitedHealth Group Inc Guides 2009 Commercial Enrollment down 1-1.5M y/y; Full year decline of 450-800K commercial risk based members- Sees 2009 Medicare advantage enrollemnt up 10-135K y/y - Sees 2009 Medicade more...
  
• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...